

Amend the claims as follows:

--7. (FOUR TIMES AMENDED) A peptide compound comprising a sequence of at least 8 consecutive amino acids, said peptide being able to induce a specific anti-tumoral T-cell immune response, the amino acid sequence being selected from the group consisting of SLFEGIDIY (SEQ ID No 1) and SLFEGIDIYT (SEQ ID No 2).--

Cancel claim 8.

Cancel claim 9.

--10. (THREE TIMES AMENDED) The peptide compound as claimed in claim 7, wherein the amino acid sequence is SEQ ID No. 1.--

--11. (FOUR TIMES AMENDED) The peptide compound as claimed in claim 7, further comprising at least one element selected from the group consisting of:

- a protective chemical group able to protect peptides against proteases and reacting with NH<sub>2</sub> or COOH, or with both NH<sub>2</sub> and COOH, provided that this modification does not significantly lower the immunogenicity of the peptide,

- chemical groups improving the effectiveness of a vaccine in vivo,

- lipids or fatty acids, covalently linked to the peptide fragments so as to form lipopeptides,

- a carrier protein possessing restriction sites and enabling intact peptide fragments to be conveyed to their sites of action in the body.--

--34. (THREE TIMES AMENDED) A method for systemic immunization of a tumor(s), comprising administering to a patient a medicinal product comprising a peptide compound comprising a sequence of at least 8 consecutive amino acids, the amino acid sequence being selected from the group consisting of SLFEGIDIY (SEQ ID No 1) and SLFEGIDIYT (SEQ ID No 2), and wherein the peptide compound brings about a specific T-cell immune response.--

--35. (THREE TIMES AMENDED) A method for immunizing by direct injection in a tumor(s), comprising administering to a patient a medicinal product comprising a sequence of at least 8 consecutive amino acids, the amino acid sequence being selected from the group consisting of SLFEGIDIY (SEQ ID No 1) and SLFEGIDIYT (SEQ ID No 2), and